Sayed-Tabatabaei FA[au] - Search Results

Year	Number of Results
1999	2
2003	1
2004	4
2005	7
2006	4
2007	9
2008	3
2009	1
2012	3
2013	2
2022	0

1

ACE polymorphisms.

Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. Sayed-Tabatabaei FA, et al. Circ Res. 2006 May 12;98(9):1123-33. doi: 10.1161/01.RES.0000223145.74217.e7. Circ Res. 2006. PMID: 16690893 Review.

2

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals.

Ebbers HC, Mantel-Teeuwisse AK, Sayed-Tabatabaei FA, Moors EH, Schellekens H, Leufkens HG. Ebbers HC, et al. Among authors: sayed tabatabaei fa. Eur J Clin Pharmacol. 2013 Feb;69(2):217-26. doi: 10.1007/s00228-012-1317-3. Epub 2012 Jun 17. Eur J Clin Pharmacol. 2013. PMID: 22706615 Free PMC article.

3

Additional risk minimisation measures in the EU - are they eligible for assessment?

Zomerdijk IM, Trifirò G, Sayed-Tabatabaei FA, Sturkenboom MC, Straus SM. Zomerdijk IM, et al. Among authors: sayed tabatabaei fa. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1046-53. doi: 10.1002/pds.3494. Epub 2013 Aug 15. Pharmacoepidemiol Drug Saf. 2013. PMID: 23946274

4

A cohort study exploring determinants of safety-related regulatory actions for biopharmaceuticals.

Ebbers HC, Mantel-Teeuwisse AK, Moors EH, Sayed Tabatabaei FA, Schellekens H, Leufkens HG. Ebbers HC, et al. Among authors: sayed tabatabaei fa. Drug Saf. 2012 May 1;35(5):417-27. doi: 10.2165/11597850-000000000-00000. Drug Saf. 2012. PMID: 22506566

5

Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Zomerdijk IM, Sayed-Tabatabaei FA, Trifirò G, Blackburn SC, Sturkenboom MC, Straus SM. Zomerdijk IM, et al. Among authors: sayed tabatabaei fa. Drug Saf. 2012 Apr 1;35(4):299-314. doi: 10.2165/11594560-000000000-00000. Drug Saf. 2012. PMID: 22339506

6

The impact of apolipoprotein E on dementia in persons with Down's syndrome.

Coppus AM, Evenhuis HM, Verberne GJ, Visser FE, Arias-Vasquez A, Sayed-Tabatabaei FA, Vergeer-Drop J, Eikelenboom P, van Gool WA, van Duijn CM. Coppus AM, et al. Among authors: sayed tabatabaei fa. Neurobiol Aging. 2008 Jun;29(6):828-35. doi: 10.1016/j.neurobiolaging.2006.12.013. Epub 2007 Jan 23. Neurobiol Aging. 2008. PMID: 17250929

7

The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis.

López León S, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM. López León S, et al. Among authors: sayed tabatabaei fa. Biol Psychiatry. 2005 May 1;57(9):999-1003. doi: 10.1016/j.biopsych.2005.01.030. Biol Psychiatry. 2005. PMID: 15860340

8

Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia.

van de Garde EM, Endeman H, Deneer VH, Biesma DH, Sayed-Tabatabaei FA, Ruven HJ, Leufkens HG, van den Bosch JM. van de Garde EM, et al. Among authors: sayed tabatabaei fa. Chest. 2008 Jan;133(1):220-5. doi: 10.1378/chest.07-1400. Epub 2007 Oct 1. Chest. 2008. PMID: 17908703

9

Angiotensin converting enzyme gene, smoking and mortality in a population-based study.

Arias-Vásquez A, Sayed-Tabatabaei FA, Schut AF, Hofman A, Bertolli-Avella AM, Vergeer JM, Aulchenko YS, Witteman JC, van Duijn CM. Arias-Vásquez A, et al. Among authors: sayed tabatabaei fa. Eur J Clin Invest. 2005 Jul;35(7):444-9. doi: 10.1111/j.1365-2362.2005.01515.x. Eur J Clin Invest. 2005. PMID: 16008546

10

The alpha-adducin gene is associated with macrovascular complications and mortality in patients with type 2 diabetes.

Yazdanpanah M, Sayed-Tabatabaei FA, Hofman A, Aulchenko YS, Oostra BA, Stricker BH, Pols HA, Lamberts SW, Witteman JC, Janssen JA, van Duijn CM. Yazdanpanah M, et al. Among authors: sayed tabatabaei fa. Diabetes. 2006 Oct;55(10):2922-7. doi: 10.2337/db06-0302. Diabetes. 2006. PMID: 17003363

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results